Leveraging Immunotherapy and EGFR Targeted Treatment in Unresectable Stage III NSCLC

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/BVU865. EBAC/CME credit will be available until October 7, 2025.

Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.